195 related articles for article (PubMed ID: 27888146)
21. Autotaxin (ATX): a multi-functional and multi-modular protein possessing enzymatic lysoPLD activity and matricellular properties.
Yuelling LM; Fuss B
Biochim Biophys Acta; 2008 Sep; 1781(9):525-30. PubMed ID: 18485925
[TBL] [Abstract][Full Text] [Related]
22. Novel point mutations attenuate autotaxin activity.
Koh E; Bandle RW; Roberts DD; Stracke ML; Clair T
Lipids Health Dis; 2009 Feb; 8():4. PubMed ID: 19222837
[TBL] [Abstract][Full Text] [Related]
23. ATX expression and LPA signalling are vital for the development of the nervous system.
Fotopoulou S; Oikonomou N; Grigorieva E; Nikitopoulou I; Paparountas T; Thanassopoulou A; Zhao Z; Xu Y; Kontoyiannis DL; Remboutsika E; Aidinis V
Dev Biol; 2010 Mar; 339(2):451-64. PubMed ID: 20079728
[TBL] [Abstract][Full Text] [Related]
24. Autotaxin, Pruritus and Primary Biliary Cholangitis (PBC).
Sun Y; Zhang W; Evans JF; Floreani A; Zou Z; Nishio Y; Qi R; Leung PS; Bowlus CL; Gershwin ME
Autoimmun Rev; 2016 Aug; 15(8):795-800. PubMed ID: 27019050
[TBL] [Abstract][Full Text] [Related]
25. Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.
Albers HM; Dong A; van Meeteren LA; Egan DA; Sunkara M; van Tilburg EW; Schuurman K; van Tellingen O; Morris AJ; Smyth SS; Moolenaar WH; Ovaa H
Proc Natl Acad Sci U S A; 2010 Apr; 107(16):7257-62. PubMed ID: 20360563
[TBL] [Abstract][Full Text] [Related]
26. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
27. Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.
Parrill AL; Echols U; Nguyen T; Pham TC; Hoeglund A; Baker DL
Bioorg Med Chem; 2008 Feb; 16(4):1784-95. PubMed ID: 18036821
[TBL] [Abstract][Full Text] [Related]
28. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
Samadi N; Gaetano C; Goping IS; Brindley DN
Oncogene; 2009 Feb; 28(7):1028-39. PubMed ID: 19079345
[TBL] [Abstract][Full Text] [Related]
29. Structure-function relationships of autotaxin, a secreted lysophospholipase D.
Hausmann J; Perrakis A; Moolenaar WH
Adv Biol Regul; 2013 Jan; 53(1):112-7. PubMed ID: 23069371
[TBL] [Abstract][Full Text] [Related]
30. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway.
Siwak DR; Shishodia S; Aggarwal BB; Kurzrock R
Cancer; 2005 Aug; 104(4):879-90. PubMed ID: 16007726
[TBL] [Abstract][Full Text] [Related]
31. Anticancer activity of FTY720: phosphorylated FTY720 inhibits autotaxin, a metastasis-enhancing and angiogenic lysophospholipase D.
van Meeteren LA; Brinkmann V; Saulnier-Blache JS; Lynch KR; Moolenaar WH
Cancer Lett; 2008 Aug; 266(2):203-8. PubMed ID: 18378389
[TBL] [Abstract][Full Text] [Related]
32. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
33. Development of an activity-based probe for autotaxin.
Cavalli S; Houben AJ; Albers HM; van Tilburg EW; de Ru A; Aoki J; van Veelen P; Moolenaar WH; Ovaa H
Chembiochem; 2010 Nov; 11(16):2311-7. PubMed ID: 20941725
[TBL] [Abstract][Full Text] [Related]
34. Design, synthesis, and biological evaluation of 2,4-dihydropyrano[2,3-c]pyrazole derivatives as autotaxin inhibitors.
Pantsar T; Singha P; Nevalainen TJ; Koshevoy I; Leppänen J; Poso A; Niskanen JMA; Pasonen-Seppänen S; Savinainen JR; Laitinen T; Laitinen JT
Eur J Pharm Sci; 2017 Sep; 107():97-111. PubMed ID: 28687529
[TBL] [Abstract][Full Text] [Related]
35. Expression and transcriptional regulation of the PD-Ialpha/autotaxin gene in neuroblastoma.
Kawagoe H; Stracke ML; Nakamura H; Sano K
Cancer Res; 1997 Jun; 57(12):2516-21. PubMed ID: 9192834
[TBL] [Abstract][Full Text] [Related]
36. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
[TBL] [Abstract][Full Text] [Related]
37. [Clinical introduction of lysophosphatidic acid and autotaxin assays].
Yatomi Y
Rinsho Byori; 2010 Jun; 58(6):631-5. PubMed ID: 20662276
[TBL] [Abstract][Full Text] [Related]
38. Regulation and biological activities of the autotaxin-LPA axis.
van Meeteren LA; Moolenaar WH
Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
[TBL] [Abstract][Full Text] [Related]
39. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
40. Blocking gp130 signaling suppresses autotaxin expression in adipocytes and improves insulin sensitivity in diet-induced obesity.
Sun S; Wang R; Song J; Guan M; Li N; Zhang X; Zhao Z; Zhang J
J Lipid Res; 2017 Nov; 58(11):2102-2113. PubMed ID: 28874440
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
